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Previewslong-lasting effect of CASIN treatment is
reminiscent of acquisition of a stable
memory phenotype. However, a lasting
memory effect, which needs to be trans-
mitted through multiple cell divisions to
daughter cells, would require inheritable
epigenetic modifications to HSC chro-
matin. As Cdc42 is known to alter acetyla-
tion of histone H4 (Alberts et al., 1998),
Florian et al. investigated whether treat-
ment with CASIN resulted in epigenetic
modification of H4. They found that,
indeed, young HSCs contain high levels
of acetylated lysine 16 on H4 (AcH4K16),
while AcH4K16 levels in aged HSCs
were substantially reduced. However,
treatment with the Cdc42-specific inhib-
itor CASIN restored levels of AcH4K16
to those observed in young HSCs.
Although the results of the study by
Florian et al. are striking and uncover
new mechanistic insights in the process
of stem cell aging with the potential
for pharmacological alteration of this
process, it would be premature to draw
conclusions about therapeutic applica-
tions at this stage. Further investigation482 Cell Stem Cell 10, May 4, 2012 ª2012 Elis needed to address many remaining
issues. For example, it is not known
whether CASIN-treated cells are able to
reduce the incidence of age-related
diseases, such as hematological malig-
nancies. In addition, the aging pheno-
types in other tissues, such as the skin,
heart, and brain, were not assayed in
this study. Because Cdc42 activity is
also increased in other tissues in this
mouse model, it would be interesting to
determine whether their aging pheno-
types can also be reversed with a similar
treatment. Finally, several outstanding
questions remain. What implications
could the discovery of a reversible aging
phenotype have for the future? Are we
getting closer to the elixir of eternal youth?
The answers to these questions will
depend on whether similar effects on
stem cell rejuvenation apply for human
hematopoietic cells and whether CASIN
can even be safely administered to
humans. Thus, many more preclinical
and clinical studies will need to be per-
formed before we can take advantage
of this important finding to devise asevier Inc.treatment that ameliorates age-related
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Human prostate cancers contain multiple cell populations marked by varying levels of the differentiation
marker prostate-specific antigen (PSA). In this issue ofCell Stem Cell, Qin et al. (2012) show that PSA/lo cells
are enriched for cells with tumor-initiating characteristics and may participate in resistance to androgen-
ablative therapies.The observation that the prostate is
capable of undergoing multiple cycles of
castration-dependent regression and
testosterone-induced regrowth suggests
the existence of hormone-independent
prostate stem cells (Isaacs, 2008).
Although unproven, it has been specu-
lated that prostate cancer may arise in
these hormone-independent stem cells.
Independent of questions regarding cell
of origin, there is increasing evidence
that prostate cancers in both rodentmodels and humans are maintained by
cellular populations that display stem
cell properties. However, the biological
nature and clinical relevance of the puta-
tive prostate cancer stem cells remains
elusive. In this issue of Cell Stem Cell,
Dean Tang and colleagues (Qin et al.,
2012) utilize a PSA promoter-driven lenti-
virus reporter system to test the relative
contribution of tumor cell subpopulations
in generating hormone refractory disease.
They demonstrate that in human prostatecancers, the PSA/lo cancer cell popula-
tion contains tumor propagating ‘‘cancer
stem cells’’ (CSCs) that resist castration.
Prostate-specific antigen (PSA) is an
androgen-regulated, tissue-specific pro-
duct of differentiated prostate cells that
is secreted into the blood. Serum PSA
has long been utilized in the early detec-
tion of prostate cancer and is a clinically
useful biomarker to follow the course of
prostate cancer in men. While serum
PSA levels positively correlate with overall
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Previewsprostate cancer tumor ‘‘burden,’’ pre-
vious studies have suggested that PSA
is predominantly produced by differenti-
ated prostate cells. The Gleason Score
is a pathologic grading system, and a
high Gleason score is associated with
undifferentiated tumors with an aggres-
sive clinical course (Abrahamsson et al.,
1988). Supporting this, Qin et al. demon-
strate a reciprocal relationship between
tumor grade as reflected by the Gleason
Score and cellular PSA expression.
Utilizing a PSA promoter-driven lentiviral
reporter system, they demonstrate in
both established prostate cancer cell
lines and primary prostate cancer tissues
that the PSA/low cells are enriched for
cells with properties characteristic of
CSCs. These PSAlo cells can undergo
asymmetric renewal, generating undiffer-
entiated PSAlo cells and more differenti-
ated PSA+ cells, which also express
Numb, a protein that inhibits Notch sig-
naling. Furthermore, as demonstrated by
clonogenic assays, PSAlo cells are more
resistant to chemotherapy than PSA+
cells. Compared with PSA+ cells, the
PSA/low cells are relatively quiescent
and display increased expression of a
number of known stem cell regulatory
genes, including Nanog, ASCL1, NKX3.1,
and TBX15. In addition, these cells over-
express known CSC markers, including
ALDH1, CD44, a2b-integrin, and Lrig1,
the latter having recently been described
as a marker of quiescent intestinal stem
cells located at the base of colonic crypts
(Powell et al., 2012). Qin et al. demon-
strate that PSA/low populations can be
further enriched for cells with tumor-initi-
ating capacity by selecting for cells within
this population that are ALDH+/CD44+/
a2b1+, with as few as 10 cells with that
phenotype forming tumors in NOD/SCID
mice. Although both PSA+ and PSA/low
cells form tumors in NOD/SCID mice,
only the PSA/low cells form tumors upon
serial passaging. These experiments
demonstrate that serial passage may be
necessary to discriminate proliferating
progenitors from self-renewing CSCs.
Furthermore, in mice deprived of an-
drogen by castration and administration
of the antiestrogen bicalutamide, PSAlo
cells grew much more readily then
PSA+ cells. These mice recapitulate the
typical clinical course of prostate cancerpatients, where castration initially
decreases serum PSA and enriches PSAlo
cells. This is inevitably followed by devel-
opment of hormone-resistant disease
characterized by rising serum PSA. This
increase in serum PSA may reflect
increasing tumor bulk because PSA/lo
primitive cells generate PSA-expressing,
differentiated progeny.
Although the studies of Qin et al.
provide novel insights into the nature of
prostate CSCs and their role in androgen
resistance, several outstanding questions
remain. The identity of the cell of origin for
human prostate cancer remains unclear
and has been further complicated by
conflicting reports suggesting either a
luminal or a basal stem cell as the cell of
origin. In fact, recent studies have sug-
gested that there may exist both luminal
and basal stem cells in the human pros-
tate and that prostate cancers may origi-
nate in either of these cell types (Maitland
et al., 2011). Molecular profiling has
yielded insights into genetic changes
underlying human prostate cancer. Based
on these studies, mouse models employ-
ing tissue-specific disruption of PTEN
and p53 generate prostate cancers with
phenotypes resembling those found in
humans. Interestingly, both of these
mutations have been found to be impor-
tant regulators of CSCs in these mouse
models as well as in other tumors, and
these findings need to be validated using
human samples. In addition, TMPRSS2/
ETS has recently been identified as a
fusion gene, which along with related
members, is found in the majority of
human prostate cancers (Tomlins et al.,
2007). It remains unclear what role, if
any, these fusion proteins may play in
the regulation of normal and malignant
prostate stem cells. A number of other
mutations have been described in pros-
tate cancer, suggesting the possibility
that different tumors may contain CSCs
with different characteristics. In addition,
genetic instability in these CSC popula-
tions may lead to clonal heterogeneity of
CSCs in individual patients.
It has been postulated that paracrine
loops may mediate interactions between
androgen-receptor-expressing, differen-
tiated prostate cells and prostate stem
cells that do not express this receptor.
An analogous situation is found in theCell Stem Cebreast where the mitogenic effects of
estrogen and progesterone on the stem
cell populations are mediated by para-
crine signaling loops involving steroid-
hormone-induced growth factors such
as fibroblast growth factor (FGF), Wnt,
and RANK-L. The NFkB pathway has
recently been reported to play an impor-
tant role in the regulation of prostate
stem cells (Rajasekhar et al., 2011). It
remains to be determined if androgens
regulate PSA/lo CSCs through paracrine
mechanisms.
Androgen deprivation remains a main-
stay of prostate cancer treatment.
Despite significant clinical benefit in the
majority of patients, androgen resistance
inevitably develops. The mechanisms
responsible for this resistance are
undoubtedly multifactorial and include
mutations of the androgen receptor
gene and alterations in androgen metab-
olism (Tombal, 2011). The studies of
Qin et al., as well as others, suggest
that an additional important mechanism
of resistance resides in the androgen-
independent prostate CSC population.
If this is the case, then more effective
treatments and ultimate cures of prostate
cancer may require the targeting and
elimination of this cell population utilizing
strategies independent of androgen
signaling.
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